As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense
With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. Playing defense, ImmunityBio is touting its Anktiva combo’s unique duration of response performance.
With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. Playing defense, ImmunityBio is touting its Anktiva combo’s unique duration of response performance.
